---
document_datetime: 2023-09-21 18:50:26
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/docetaxel-teva-pharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: docetaxel-teva-pharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.987921
conversion_datetime: 2025-12-23 01:21:35.11328
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Docetaxel Teva Pharma

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|-----------|
| IB/0007/G            | To update section 4.4 to add warning on cystoid macular oedema based on the results of safety cumulative reviews conducted by the innovator's MAH and section 4.8 of the SmPC to include cystoid macular oedema and hyponatraemia in the list of adverse reactions following assessment by the CHMP for the originator product Taxotere. The Package Leaflet is updated accordingly. In addition the product information has been brought in line with the latest product | 10/10/2013                          |                                                | SmPC and PL                      |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

United Kingdom Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | marketing authorisation numbers. In addition, minor linguistic amendments were carried out in the CS, FI, RO annexes. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                   | longer authorised                               |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| IAIN/0005 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 23/05/2013 n/a                                  |
| IAIN/0003 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 22/06/2012 n/a Annex II and PL no               |
| IB/0002   | Update of SmPC section 4.5 regarding interaction between docetaxel and ritonavir as well as update of SmPC section 4.8 regarding the risk of renal dysfunction, respiratory disorders, persisting alopecia and the frequency for leukaemia/MDS in the post- marketing section in accordance with the update for the reference product. The package leaflet has been updated accordingly. In addition, the MAH took the opportunity to update the PI in line with QRD version 8 as well as to introduce corrections to SmPC section 4.8 in line with the reference poduct. Furthermore, the contact details of the LoLR in the package leaflet have been updated C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product | 10/05/2012 n/a SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|         | product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                    |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| IB/0001 | Update of SmPC sections 4.4 and 4.8 following the final results of study TAX 316 in accordance with the update for the reference product Taxotere. In addition, the MAH took the opportunity to update the list of local representatives and Annex II. Furthermore, corrections have been introduced in the following languages: BG, CS, HU, PT, RO and DA. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH | 03/02/2012 n/a SmPC, II and longer |

<!-- image -->